Latest Conference Articles

The study revealed that patients meeting fibromyalgia criteria or displaying fibromyalgia-like symptoms were less likely to meet standardized response criteria with biologic therapy.

Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.

Christian Ruff, MD, MPH discusses results from the phase 2 AZALEA-TIMI 71 trial, the need for new antithrombotic therapies, and the net clinical benefit outcome of abelacimab for AF.

Diana Abdueva, PhD, states selecting the right therapy for rheumatoid arthritis is a complex challenge due to both the economic burden of therapies and the trial-and-error process patients often undergo.

The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.

Ryan DeMasi, MD, explained despite the patients' shorter disease duration, they exhibited severe symptoms, prompting a more aggressive early intervention approach using treatment with upadacitinib.

The study author discusses the impact of findings showing MASH resolution without worsening fibrosis is a surrogate endpoint for 15-year bariatric surgery survival.

Ryan DeMasi, MD, explained the direct and indirect effects of upadacitinib and adalimumab on pain in patients with rheumatoid arthritis.

Viet Le, DMSc, PA-C, discusses early data from the Target-D trial and how this might influence the way he interprets the findings from other vitamin D supplementation studies.

In an interview at AHA 2023, Deepak Bhatt, MD, MPH, discusses recent advancements in cardiovascular risk management, with a focus on the evolving recognition of inflammation, Lp(a), and obesity as modifiable risk factors.

Loomba discusses how practices like his own are adapting to the new nomenclature in metabolic-associated liver disease.

A new study from the GALA cohort shows serum bile acid's association with clinical outcomes is relevant in the context of IBAT inhibitor therapy.

Sanyal discusses the makeup of retatrutide and its potential for patients with fatty liver disease and comorbid metabolic conditions.

Patients with PsA in the self-reported racial and ethnic minority were less likely to be diagnosed within 12 months of symptom onset and were more frequently uninsured compared with White patients .

Ahmad Masri, MD, MS, discusses a study he led examining disparities in time to diagnosis of hypertrophic cardiomyopathy using Medicare claims data.

An artificial intelligence can detect increased fluid in lungs by simply hearing voice changes over time—and the increased fluid in lungs can be a sign of heart failure.

Compared to their usual diet, participants placed in the low sodium diet group—required to keep their sodium intake to 500 mg daily—had their blood pressure reduced by 6 mm Hg.

Jawaheer and her team used pre-pregnancy data to determine whether there are gene expression biomarkers at the pre-pregnancy baseline that can predict improvement or worsening during pregnancy in patients with rheumatoid arthritis.

FDA approved sotaglifozin (INPEFA®) on May 26, 2023, to treat heart failure. Also, a phase 3 trial shows the clinical benefits of the drug by the 3-month mark.

Results showed decreased mortality rates among patients with severe alcohol-associated hepatitis treated with corticosteroids after the COVID-19 pandemic.

Pooled data from The Liver Meeting showed odevixibat sustains itch and serum bile acid benefits in patients with Alagille syndrome. An investigators shares what he wants to learn next.

Results of ARIES-HM3 demonstrate use of aspirin was associated with an increased rate of major bleeding following HeartMate 3 implantation.

Sumera Ilyas, MBBS, discussed cholangiocarcinoma in primary sclerosing cholangitis and the need for global efforts to improve access to more advanced diagnostic testing.

Post hoc phase 2b analyses suggest peogzafermin may benefit severe fibrosis regardless of MASH patients' cirrhosis status.

In this episode, hosts sit down between sessions at AHA 2023 to discuss the landmark SELECT trial, their interpretation of the data, and its implications for care moving forward. Later in the episode, hosts break down the DAPA-MI trial.

We sat down with Jessica Ferrell, PhD, to discuss key takeaways from her session about the developing role of bile acids both for and beyond cholestatic and metabolic diseases.

Retatrutide, an investigational triple-agonist therapy, may help resolve liver fat prior to progression to severe disease.

Results from this prospective study in Japan found older age, history of hepatocellular carcinoma, and decreased albumin level at SVR were significantly associated with liver-related mortality after SVR.